55 related articles for article (PubMed ID: 35594806)
1. First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence.
Murillo-Zamora E; Trujillo X; Huerta M; Ríos-Silva M; Lugo-Radillo A; Baltazar-Rodríguez LM; Mendoza-Cano O
Public Health; 2022 Jun; 207():105-107. PubMed ID: 35594806
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 Pneumonia in Fully Vaccinated Adults during the Dominance of the Omicron Sublineages BA.1.1 and BA.2 in Mexico.
Murillo-Zamora E; Trujillo X; Huerta M; Riós-Silva M; Guzmán-Esquivel J; Bricio-Barrios JA; Mendoza-Cano O; Lugo-Radillo A
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013594
[TBL] [Abstract][Full Text] [Related]
4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
5. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
6. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.
Dag Berild J; Bergstad Larsen V; Myrup Thiesson E; Lehtonen T; Grøsland M; Helgeland J; Wolhlfahrt J; Vinsløv Hansen J; Palmu AA; Hviid A
JAMA Netw Open; 2022 Jun; 5(6):e2217375. PubMed ID: 35699955
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
[TBL] [Abstract][Full Text] [Related]
10. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
[TBL] [Abstract][Full Text] [Related]
11. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
[TBL] [Abstract][Full Text] [Related]
12. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
[TBL] [Abstract][Full Text] [Related]
13. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
Kim JY; Lim SY; Park S; Kwon JS; Bae S; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Kim K; Shum D; Jee Y; Kim SH
J Infect Dis; 2022 Mar; 225(5):777-784. PubMed ID: 34850034
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.
Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
[TBL] [Abstract][Full Text] [Related]
16. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
17. Decreased risk of COVID-19 pneumonia in children and adolescents during the Delta variant emergence.
Murillo-Zamora E; Trujillo X; Huerta M; Ríos-Silva M; Baltazar-Rodríguez LM; Guzmán-Esquivel J; Benites-Godínez V; Ortega-Ramírez AD; Mendoza-Cano O
Public Health; 2022 Mar; 204():9-11. PubMed ID: 35085915
[TBL] [Abstract][Full Text] [Related]
18. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
20. Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults.
Murillo-Zamora E; Sánchez-Piña RA; Trujillo X; Huerta M; Ríos-Silva M; Mendoza-Cano O
Int J Infect Dis; 2022 May; 118():244-246. PubMed ID: 35167967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]